Insights On Enterprise Solutions

1. Smarter CMC Strategies To Accelerate Next-Gen Biologics To The Clinic 10/23/2025

   Learn how process design and cross-functional collaboration mitigate risks and accelerate the path from early development to FIH manufacturing through real-world case studies of practical approaches.

2. Your Journey To GMP With Emphasis On Linker Payload Development 10/22/2025

   Develop lower risk strategies with our insights into the key considerations you need to factor in when conjugating your linker payload to its antibody in our review of the pros and cons of semi-synthetic and synthetic linker payloads.

3. Custom Designed Linker-Payload Synthesis And Bioconjugation 10/22/2025

   Achieve ADC development with an integrated approach to linker-payload design and synthesis. Learn how custom synthesis and a bioconjugation strategy accelerate candidate selection and GMP manufacturing.

4. Identification Of New Classes Of Maytansinoid Payloads For ADCs 10/22/2025

   See how a successful collaboration led to the design of novel, cell-permeable maytansine-based payloads for ADCs. These new tubulin inhibitors were engineered to enhance the critical "bystander killer effect."

5. Essential Insights Into Linker Chemistry For ADCs 10/22/2025

   The linker is key to an ADC's success, influencing stability and targeted drug release. Explore the evolution of linker chemistry, from cleavable mechanisms to site-specific conjugation, and learn why rigorous assessment is critical.

6. Optimizing CMC Strategy For Successful Scale-Up 10/22/2025

   In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) share advice on developing CMC strategies in a way that strengthens manufacturability through careful assay development and collaboration with CDMOs.

7. Developing Analytical Methods For Advanced ADCs 10/22/2025

   Advanced molecules, especially ADCs with novel constructs, require extensive characterization testing. In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) discuss the nuances of analytical methodology for advanced ADCs and emphasize the importance of potency assays. They also share their thoughts on how much CMC development companies should aim to do internally before working with development partners.

8. CMC Challenges Facing Next-Generation ADCs 10/22/2025

   In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) weigh in on the biggest challenges to ADC development, particularly navigating geopolitical tensions in a time of increasingly global manufacturing operations.

9. Game-Changing CLD Platforms: Strategies, Technologies, Workflows 10/21/2025

   Selecting the right cell line platform is complex. Learn how flexible strategies, integrated technologies, and expert workflows enable high productivity, rapid timelines, and a de-risked path to clinical success.

10. Collaboration An Untapped Fuel For Driving Biopharma R&D 10/20/2025

    Biopharma’s future depends on collaboration. Discover how cross-industry partnerships and shared resources can accelerate innovation, overcome talent gaps, and strengthen the global R&D ecosystem.